KIT-D816V–independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Systemic mastocytosis (SM) either presents as a malignant neoplasm with short survival or as an indolent disease with normal life expectancy. In both instances, neoplastic mast cells (MCs) harbor D816V-mutated KIT, suggesting that additional oncogenic mechanisms are involved in malignant transformation. We here describe that Lyn and Btk are phosphorylated in a KIT-independent manner in neoplastic MCs in advanced SM and in the MC leukemia cell line HMC-1. Lyn and Btk activation was not only detected in KIT D816V-positive HMC-1.2 cells, but also in the KIT D816V-negative HMC-1.1 subclone. Moreover, KIT D816V did not induce Lyn/Btk activation in Ba/F3 cells, and deactivation of KIT D816V by midostaurin did not alter Lyn/Btk activation. siRNAs against Btk and Lyn were found to block survival in neoplastic MCs and to cooperate with midostaurin in producing growth inhibition. Growth inhibitory effects were also obtained with 2 targeted drugs, dasatinib which blocks KIT, Lyn, and Btk activation in MCs, and bosutinib, a drug that deactivates Lyn and Btk without blocking KIT activity. Together, KIT-independent signaling via Lyn/Btk contributes to growth of neoplastic MCs in advanced SM. Dasatinib and bosutinib disrupt Lyn/Btk-driven oncogenic signaling in neoplastic MC, which may have clinical implications and explain synergistic drug interactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In Philadelphia+ acute lymphocytic leukemia (ALL) cells, tyrosine kinase inhibitors (e.g., dasatinib, bosutinib) with SFK inhibitory activity26 diminish MCL-1 expression and induce apoptosis.27”
From Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia (2025) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Valent, P., Akin, C., Escribano, L., Födinger, M., Hartmann, K., Brockow, K., Castells, M., Sperr, W. R., Kluin‐Nelemans, H. C., Hamdy, N. A. T., et al. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01807.x · Cited by 750 · cited 1×
“Multiplex RT-PCR (mDx Hema Vision; Bio-Rad Laboratories) was applied to seek for leukemia-related defects in HMC-1 cells: t(X;11), t(4;11), t(6;11), t(11;19), t(10;11), t(1;11), t(11;17), t(9;11), t(1;19), t(17;19), t(12;21), TAL1, t(8;21), t(3;21), t(16;21), t(15;17)(bcr1 bcr3), t(5;17), t(6;9), t(9;9), inv(16), t(9;…”
Self-citationMetcalfe, D. D. (2008) · Blood · doi:10.1182/blood-2007-11-078097 · Cited by 536
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib
Hantschel, O., Rix, U., Schmidt, U., Bürckstümmer, T., Kneidinger, M., Schütze, G., Colinge, J., Bennett, K. L., Ellmeier, W., Valent, P., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702654104 · Cited by 284
Self-citationLinnekin, D., DeBerry, C. S., & Mou, S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.43.27450 · Cited by 161
Cited by
Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
Valent, P., Akin, C., & Metcalfe, D. D. (2017) · Blood · doi:10.1182/blood-2016-09-731893 · Cited by 592
Self-citationComprehensive mutational profiling in advanced systemic mastocytosis
Schwaab, J., Schnittger, S., Sotlar, K., Walz, C., Fabarius, A., Pfirrmann, M., Kohlmann, A., Grossmann, V., Meggendorfer, M., Horny, H.-P., et al. (2013) · Blood · doi:10.1182/blood-2013-04-496448 · Cited by 263
Self-citationMidostaurin: a magic bullet that blocks mast cell expansion and activation
Valent, P., Akin, C., Hartmann, K., George, T. I., Sotlar, K., Peter, B., Gleixner, K. V., Blatt, K., Sperr, W. R., Manley, P. W., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx290 · Cited by 79
“For example, the synergistic effect of the drug combination ‘midostaurinþ dasatinib’ was explained by inhibitory effects of dasatinib on BTK and LYN, since cooperative drug effects (midostaurinþ dasatinib) were also obtained when applying the drug plus small interfering RNA (siRNA), namely ‘midostaurinþBTK-siRNA’ or ‘…”
BackgroundSelf-citationSelected recent advances in understanding the role of human mast cells in health and disease
Levi-Schaffer, F., Gibbs, B. F., Hallgren, J., Pucillo, C., Redegeld, F., Siebenhaar, F., Vitte, J., Mezouar, S., Michel, M., Puzzovio, P. G., et al. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.01.030 · Cited by 51
Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia
Hu, X., Li, L., Nkwocha, J., Kmieciak, M., Shang, S., Cowart, L. A., Yue, Y., Horimoto, K., Hawkridge, A., Rijal, A., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02125-x · Cited by 15
Metadata
- Authors
- Gleixner, K. V., Mayerhofer, M., Cerny-Reiterer, S., Hörmann, G., Rix, U., Bennett, K. L., Hadzijusufovic, E., Meyer, R. A., Pickl, W. F., Gotlib, J., Horny, H.-P., Reiter, A., Mitterbauer-Hohendanner, G., Superti-Furga, G., & Valent, P.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2011-08-18
- Volume
- 118
- Issue
- 7
- Pages
- 1885-1898
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1970370827
- Cited by
- 73
- References
- 4
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: KIT-D816V–independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. https://app.cochat.ai/papers/10.1182/blood-2010-06-289959
- The paper
- Gleixner, K. V., Mayerhofer, M., Cerny-Reiterer, S., Hörmann, G., Rix, U., Bennett, K. L., Hadzijusufovic, E., Meyer, R. A., Pickl, W. F., Gotlib, J., Horny, H.-P., Reiter, A., Mitterbauer-Hohendanner, G., Superti-Furga, G., & Valent, P. (2011). KIT-D816V–independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood. https://doi.org/10.1182/blood-2010-06-289959
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.